Diabetes mellitus, hyperhomocystinemia and atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: A retrospective study

Renal Failure

Volumn 26, Issue 3, 2004, Pages 317-323

  Lee, Chil Hsiung ^a   Chang, Hsueh Wen ^b   Wang, I Kuan ^a   Lin, Chun Liang ^a   Chen, Te Chuan ^a   Wang, Pao Hui ^b   Chang, Hung Yu ^a   Chen, Jin Bor ^a   Hsu, Kuo Tai ^a   Chuang, Feng Rong ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Atherosclerotic vascular disease; Diabetes mellitus; Hemodialysis; Hyperhomocystinemia

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE INTOLERANCE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; TAIWAN; VASCULAR DISEASE;

ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TAIWAN; VASCULAR DISEASES;

EID: 3943053401     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200026741     Document Type: Article

References (31)

1. Benmerabet, S.; Fredenrich, A.; Robillon, J.F.; Canivet, B.; Candito, M.; Van Obberghen, E. Clinical relevance of homocysteine monitoring in the diabetic patients. Diabetes Metab. 2002, 28, 510-515.
2. Jeremy, J.Y.; Shukla, N.; Angelini, G.D. Homocysteine and cardiovascular disease in diabetes mellitus (comment). Atherosclerosis 2002, 164, 383-384.
3. Yeromenko, Y.; Lavie, L.; Levy, Y. Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 108-116.
4. Baliga, B.S.; Reynolds, T.; Fink, L.M.; Fonseca, V.A. Hyperhomocystinemia in type 2 diabetes mellitus; cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr. Pract. 2000, 6, 435-441.
5. Hoogeveen, E.K.; Kostense, P.J.; Jakobs, C.; Dekker, J.M.; Nijpels, G.; Heine, R.J.; Bouter, L.M.; Stehouwer, C.D.A. Hyperhomocystinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study. Circulation 2000, 707, 1506-1511.
6. Stabler, S.P.; Estacio, R.; Jeffers, B.W.; Cohen, J.A.; Allen, R.H.; Schrier, R.W. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metab. Clin. Exp. 1999, 48, 1096-1101.
7. Oishi, K.; Nagake, Y.; Yamasaki, H.; Fukuda, S.; Ichikawa, H.; Ota, K.; Makino, H. The significance of atherogenic indices in patients on hemodialysis. Am. J. Nephrol. 2000, 20, 107-115.
8. Haraki, T.; Takegoshi, T.; Kitoh, C.; Kajinami, K.; Wakasugi, T.; Hirai, J.; Shimada, T.; Kawashiri, M.; Inazu, A.; Koizumi, J.; Mabuchi, H. Hyperhomocystinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin. Nephrol. 2001, 56, 132-139.
9. Suliman, M.E.; Stenvinkel, P.; Barany, P.; Heimburger, O.; Anderstam, B.; Lindholm, B. Hyperhomocystinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am. J. Kidney Dis. 2003, 41, S89-S95.
10. Kannel, W.B.; McGee, D.L. Diabetes and cardiovascular disease. The Framingham study. J. Am. Med. Assoc. 1979, 241, 2035-2038.
11. US Renal Data System: USRDS. Annual Data Report; The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease: Bethesda, MD, 1997.
12. Shinzato, T.; Nakai, S.; Fujiwara, Y.; Takai, I.; Morita, H.; Nakanc, K.; Macda, K. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentration. Nephron 1994, 67, 280-290.
13. Loehrer, F.M.T.; Angst, C.P.; Brunner, F.P.; Haefeli, W.E.; Fowler, B. Evidence for disturbed S-adeno-sylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol. Dial. Transplant. 1998, 13, 656-661.
14. Bostom, A.G.; Shemin, D.; Lapane, K.L.; Nadeau, M.R.; Sutherland, P.; Chan, J.; Rozen, R.; Yoburn, D.; Jacques, P.F.; Sclhub, J.; Rosenberg, I.H. Folate status is the major determinant of fasting total homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996, 723, 193-202.
15. Hirose, S.; Kim, S.; Matsuda, A.; Itakura, Y.; Mitarai, T.; Isoda, K. Hyperhomocystinemia in patients on dialysis, as determined by the methionine loading test. J. Jpn. Soc. Dial. Ther. 1997, 30, 967-973.
16. Hultberg, B.; Andersson, A.; Sterner, G. Plasma homocysteine in renal failure. Clin. Nephrol. 1993, 23, 174-178.
17. Perna, A.F.; Santo, N.G.; Ingrosso, D. Adverse effect of hyperhomocystinemia and their management by folic acid. Miner. Electrolyte Metab. 1997, 23, 174-178.
18. Janssen, M.J.F.M.; Guldener, C.; Jong, G.M.T.; Berg, M.; Donker, A.J.M. Folic acid treatment of hyperhomocystinemia in dialysis patients. Miner. Electrolyte Metab. 1996, 22, 110-114.
19. Wilcken, D.E.L.; Gupta, V.J.; Reddy, S.G. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance hemodialysis. Clin. Sci. 1980, 58, 427-430.
20. Nakazono, H.; Nagake, Y.; Kumagai, I.; Ichikawa, H.; Suga, H.; Makino, H. Relationship between parameters of the urea kinetic model and serum amino acid levels in patients on hemodialysis. Clin. Exp. Nephrol. 1993, 3, 116-122.
21. Moustapha, A.; Gupta, A.; Robinson, K.; Arheart, K.; Jacobsen, D.W.; Schreiber, M.J.; Dennis, V.W. Prevalence and determinants of hyperhomocystinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999, 55, 1470-1475.
22. Robinson, K.; Gupta, A.; Dennis, V.W.; Arheart, K.; Chaudhary, D.; Green, R.; Vigo, P.; Mayer, E.L.; Selhub, J.; Kutner, M.; Jacobsen, D.W. Hyperhomocystinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996, 94, 2743-2748.
23. Bostom, A.G.; Shemin, D.; Verhoef, P.; Nadeau, M.R.; Jacques, P.P.; Selhub, J.; Dworkin, L.; Rosenberg, I.H. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Am. Heart Assoc., Inc. 1997, 69, 2554-2558.
24. Hultberg, B.; Andersson, A.; Sterner, G. Plasma homocysteine in renal failure. Clin. Nephrol. 1993, 41, 230-234.
25. Mohamed, E.S.; Bjorn, A.; Jonas, B. Evidence of taurine depletion and accumulation of cystine sulfinic acid in chronic dialysis patients. Kidney Int. 1996, 50, 1713-1717.
26. Manns, B.J.; Burgess, E.D.; BSc-Hyndman, M.E.; Parsons, H.G.; Schaefer, J.P.; Scott-Douglas, N.W. Hyperhomocystinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kidney Dis. 1999, 34, 669-677.
27. Bostom, A.G.; Lathrop, L. Hyperhomocystinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997, 52, 10-20.
28. Green, D.; Stone, N.J.; Krumlovsky, F.A. Putative atherogenic factors in patients with chronic renal failure. Prog. Cardiovasc. Dis. 1983, 26, 133-140.
29. Tamura, T.; Bergman, S.M.; Morgan, S.L. Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis. Am. J. Kidney Dis. 1998, 32, 475-481.
30. Jaar, E.G.; Hermann, J.A.; Furth, S.L.; Briggs, W.; Powe, N.R. Septicaemiae in diabetic hemodialysis patients: comparison of incidence, risk factors and mortality with nondiabetic hemodialysis patients. Am. J. Kidney Dis. 2000, 35, 282-292.
31. Ritz, E.; Lippert, J.; Keller, C. Hypertension, cardiovascular complications and survival in diabetic patients on maintenance hemodialysis. Nephrol. Dial. Transplant. 1995, 10 (Suppl. 7), 43-46.